We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 0.71% | 35.40 | 35.10 | 35.45 | 35.40 | 35.00 | 35.05 | 1,314,613 | 16:35:05 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 206.47 | 189.59M |
TIDMAPH
RNS Number : 7794U
Alliance Pharma PLC
23 January 2017
For immediate release 23 January 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Pre-Close Trading Update
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces its pre-close trading update ahead of its preliminary results for the year ended 31 December 2016.
Group revenue for 2016 is expected to be more than double the prior year at GBP97.5m (2015: GBP48.3m). This has been driven by the transformational acquisition of the ex-Sinclair products in December 2015 and the continued strong performance of the original Alliance portfolio. Trading profit before tax is expected to be in line with the Board's expectations.
The ex-Sinclair products delivered sales of approximately GBP43.8m and represented 45% of total sales, which is in line with the Board's expectations. The remaining Alliance portfolio performed strongly and delivered a sales increase of 13% to approximately GBP53.7m for the year (2015: GBP47.5m).
Group sales were enhanced by approximately GBP4.2m due to the weakening of Sterling, primarily against the Euro and US Dollar. However the effect on profits was much smaller due to the increases in cost of goods and operating costs denominated in these currencies.
Our key brands delivered a strong performance in 2016. Kelo-Cote(TM), our scar reduction product, recorded sales of GBP10.1m, exceeding GBP10m for the first time. MacuShield(TM), our nutritional supplement product for age-related macular degeneration (AMD), also performed strongly with sales of GBP5.3m for the year compared with sales of GBP3.5m in the prior eleven months following its acquisition in February 2015. On an annualised basis this would equate to a growth rate of 40%. Hydromol(TM), our emollient range, grew 6% with sales of GBP7.0m in a competitive market. We were also pleased with the sales performance of our UK Consumer Health products, including Ashton & Parsons(R) Infants' Powders whose sales grew from GBP1.5m in 2015 to GBP1.9m.
Full year free cash flow was approximately double last year at over GBP12m (2015: GBP6.3m). Cash conversion was particularly good in the second half of the year with the generation of more than GBP10m of free cash flow. The first half was affected by the normalisation of working capital movements following the acquisition of the ex-Sinclair products. The integration of operations and systems from Sinclair has progressed well and the transfer of the cash-generating activities is now complete.
Net debt decreased from GBP79.0m at 30 June 2016 to approximately GBP76.1m as at 31 December 2016, despite adverse foreign exchange movements following the weakening of Sterling. Expressed at 30 June 2016 currency rates, net debt would have been GBP73.8m. We expect net debt to progressively reduce during 2017, driven by the Group's strong underlying cash generation.
The UK registration for Diclectin, a product undergoing approval for the treatment for nausea and vomiting of pregnancy, is progressing to plan. We expect UK registration mid-year, which will enable us to begin sales in the second half of 2017 with European territories following from late 2018.
The Group expects to announce its preliminary results for the twelve months ended 31 December 2016 on Wednesday 29 March 2017.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer www.alliancepharma.co.uk + 44 (0) 20 7466 Buchanan 5000 Mark Court / Sophie Cowles / Jane Glover + 44 (0) 20 7260 Numis Securities Limited 1000 Nominated Adviser: Michael Meade / Freddie Barnfield Corporate Broking: James Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSEFFWSFWSEEF
(END) Dow Jones Newswires
January 23, 2017 02:00 ET (07:00 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions